Wedbush Reiterates “Outperform” Rating for Inozyme Pharma (NASDAQ:INZY)
Inozyme Pharma (NASDAQ:INZY – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a note issued to investors on Tuesday, Benzinga reports. They presently have a $15.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 172.73% from the stock’s previous close. Separately, Needham & […]
More Stories
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...
State Department Launches Birth Tourism Prevention Task Force
By Troy Myers The Department of State on Wednesday announced the existence of a task force that has already revoked...
Todd Blanche Sworn In as Attorney General
By Kimberly Hayek Todd Blanche, President Donald Trump’s former personal lawyer, was sworn in Monday as U.S. attorney general and...
16,000 Arrests Made as Part of Operation to Make Washington Safe
By Naveen Athrappully More than 16,000 individuals have been arrested in Washington since the launch of the Make D.C. Safe...
Commercial Chapter 11 Bankruptcy Filings Decrease Annually
By Naveen Athrappully There were 666 commercial Chapter 11 bankruptcy filings made in the United States in July, a 27...
Syrian Court Sentences Ex-President Bashar Assad to Death
By Tom Ozimek A Syrian court sentenced ousted leader Bashar al-Assad to death on Tuesday, convicting him of crimes committed...